# US 2004/0006081 A1 · Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0006081 A1
- Document ID: US20040006081A1
- Status: Published application
- Kind: A1
- Application number: 10/276,430
- Filed: 2002-12-10
- Published: 2004-01-08
- Earliest claimed: 2002-12-10
- Inventors: Jeremy Burrows; Anne Cooper; John Cumming; Thomas McInally; Howard Tucker
- Web page: https://patentgrep.com/patent/US20040006081A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/08: for leprosy
- A61P 33/06: Antimalarials
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/58: attached in position 4
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I), compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

## Claims

### Claim 1

A compound of formula (I):
64
wherein:
R1 is C1-6 alkyl, C3-7 cycloalkyl, C3-8 alkenyl or C3-8 alkynyl, each optionally substituted with one or more of: halo, hydroxy, cyano, nitro, C3-7 cycloalkyl, NR8R9, C(O)R10, NR13C(O)R14, C(O)NR17R18, NR19C(O)NR20R21, S(O)nR22, C1-6 alkoxy (itself optionally substituted by heterocyclyl or C(O)NR23R24), heterocyclyl, heterocyclyloxy, aryl, aryloxy, heteroaryl or heteroaryloxy;
R2 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl(C1-4)alkyl, heteroaryl(C1-4)alkyl or heterocyclyl(C1-4)alkyl;
R3 is C1-8 alkyl, C2-8 alkenyl, NR45R46, C2-8 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(C1-4)alkyl, heteroaryl(C1-4)alkyl or heterocyclyl(C1-4)alkyl;
R46 is C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl(C1-4)alkyl, heteroaryl(C1-4)alkyl or heterocyclyl(C1-4)alkyl;
wherein the groups of R2, R3 and R46, and the heterocyclyl, aryl and heteroaryl moieties of R1, are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, S(O)qR25, OC(O)NR26R27, NR28R29, NR30C(O)R31, NR32C(O)NR33R34, S(O)2NR35R36, NR37S(O)2R38, C(O)NR39R40, C(O)R41, CO2R42, NR43CO2R44, C1-6 alkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, phenyl, phenyl(C1-4)alkyl, phenoxy, phenylthio, phenyl(C1-4)alkoxy, heteroaryl, heteroaryl(C1-4)alkyl, heteroaryloxy or heteroaryl(C1-4)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(O)kC1-4 alkyl, S(O)2NH2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3; the C3-7 cycloalkyl, aryl, heteroaryl and heterocyclyl moieties of R1, R2 and R3 being additionally optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6 alkoxy(C1-6)alkyl;
R4, R5, R6 and R7 are, independently, hydrogen, C1-6 alkyl {optionally substituted by halo, cyano, hydroxy, C1-4 alkoxy, OCF3, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2, NHC(O)(C1-4 alkyl), N(C1-4 alkyl)C(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), N(C1-4 alkyl)S(O)2(C1-4 alkyl), CO2(C1-4 alkyl), C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, C(O)NH2, CO2H, S(O)2(C1-4 alkyl), S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, heterocyclyl or C(O)(heterocyclyl)}, S(O)2NH2, S(O)2NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, C(O)(C1-4 alkyl), CO2H, CO2(C1-4 alkyl) or C(O)(heterocyclyl); or two of R4, R5, R6 and R7 can join to form, together with the ring to which they are attached, a bicyclic ring system; or two of R4, R5, R6 and R7 can form an endocyclic bond (thereby resulting in an unsaturated ring system);
X is C(O), S(O)2, C(O)C(O), a direct bond or C(O)C(O)NR47;
k, m, n, p and q are, independently, 0, 1 or 2;
R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43 and R44 are, independently, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl each or which is optionally substituted by halo, cyano, nitro, hydroxy, C1-4 alkyl, C4 alkoxy, SCH3, S(O)CH3, S(O)2CH3, NH2, NHCH3, N(CH3)2, NHC(O)NH2, C(O)NH2, NHC(O)CH3, S(O)2N(CH3)2, S(O)2NHCH3, CF3, CHF2, CH2F, CH2CF3 or OCF3; and R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43 and R44 may additionally be hydrogen;
R8, R9, R10, R13, R14, R17, R18, R19, R20, R21, R23, R24, R45 and R47 are, independently, hydrogen, alkyl {optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, heterocyclyl or phenyl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy)}, phenyl (itself optionally substituted by halo, hydroxy, nitro, S(O)kC1-4 alkyl, S(O)2NH2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3) or heteroaryl (itself optionally substituted by halo, hydroxy, nitro, S(O)kC1-4 alkyl, S(O)2NH2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3);
R22 is alkyl {optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, heterocyclyl or phenyl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy)}, phenyl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy) or heteroaryl (itself optionally substituted by halo, hydroxy, cyano, C1-4 alkyl or C1-4 alkoxy);
the pairs of substituents: R8 and R9, R13 and R14, R17 and R18, R20 and R21, R23 and R24, R26 and R27, R28 and R29, R30 and R31, R32 with either R33 or R34, R33 and R34, R35 and R36, R37 and R38, R39 and R40 and R43 and R44 may, independently, join to form a ring and such a ring may also comprise an oxygen, sulphur or nitrogen atom;
where for any of the foregoing heterocyclic groups having a ring —N(H)— moiety, that —N(H)— moiety may be optionally substituted by C1-4 alkyl (itself optionally substituted by hydroxy), C(O)(C1-4 alkyl), C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2 or S(O)2(C1-4 alkyl);
a ring nitrogen and/or sulphur atom is optionally oxidised to form an N-oxide and/or an S-oxide;
foregoing heteroaryl or heterocyclyl rings are C- or, where possible, N-linked;
or a pharmaceutically acceptable salt thereof or a solvate thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein heteroaryl is pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, furyl, quinolinyl, isoquinolinyl, dihydroisoquinolinyl, indolyl, benzimidazolyl, benzo[b]furyl, benzo[b]thienyl, phthalazinyl, indanyl, oxadiazolyl or benzthiazolyl.

### Claim 3 (depends on 1, 2)

A compouind as claimed in claim 1 or 2 wherein aryl is phenyl.

### Claim 4 (depends on 1, 2, 3)

A compound as claimed in claim 1, 2 or 3 wherein heterocyclyl is piperidinyl, morpholinyl, pyrrolidinyl, piperazinyl or tetrahydrofuryl.

### Claim 5 (depends on 1, 2, 3, 4)

A compound as claimed in claim 1, 2, 3 or 4 wherein R4, R5, R6 and R7 are all hydrogen.

### Claim 6 (depends on 1, 2, 3, 4)

A compound as claimed in claim 1, 2, 3, 4, or 5 wherein X is C(O).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A compound as claimed in claim 1, 2, 3, 4, 5 or 6 wherein m and p are both 1.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A compound as claimed in claim 1, 2, 3, 4, 5, 6 or 7 wherein R2 is methyl, ethyl, allyl, cyclopropyl or propargyl.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A compound as claimed in claim 1, 2, 3, 4, 5, 6, 7 or 8 wherein R3 is NR45R46, aryl, heteroaryl, aryl(C1-4)alkyl or heteroaryl(C1-4)alkyl; R45 is hydrogen or C1-6 alkyl; R46 is aryl, heteroaryl, aryl(C1-4)alkyl or heteroaryl(C1-4)alkyl; wherein the aryl and heteroaryl groups of R3 and R46 are independently substituted by S(O)qR25, OC(O)NR26R27, NR32C(O)NR33R34 or C(O)R41, and optionally further substituted by one or more of halo, cyano, nitro, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy(C1-6)alkyl, S(O)qR25, OC(O)NR26R27, NR28R29, NR30C(O)R31, NR32C(O)NR33R34, S(O)2NR35R36, NR37S(O)2R38, C(O)NR39R40, C(O)R41, CO2R42, NR43CO2R44, C3-10 cycloalkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, phenyl, phenyl(C1-4)alkyl, phenoxy, phenylthio, phenyl(C1-4)alkoxy, heteroaryl, heteroaryl(C1-4)alkyl, heteroaryloxy or heteroaryl(C1-4)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(O)kC1-4 alkyl, S(O)2NH2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3; wherein q, k, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43 and R44 are as defined in claim 1.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A compound as claimed in claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 wherein R1 is 2,6-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4-dimethoxy-6-hydroxybenzyl, 3-(4-dimethylamino-phenyl)prop-2-enyl, (1-phenyl-2,5-dimethylpyrrol-3-yl)methyl, 2-phenylethyl, 3-phenylpropyl, 3-R/S-phenylbutyl, 3-cyano-3,3-diphenylpropyl, 3-cyano-3-phenylpropyl, 4-(N-methylbenzamido)-3-phenylbutyl or 3,3-diphenylpropyl.

### Claim 11 (depends on 1)

A pharmaceutical composition which comprises a compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.

### Claim 12

A compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof, for use as a medicament.

### Claim 13

A compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in therapy.

### Claim 14

A compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in modulating CCR5 receptor activity in a warm blooded animal.

### Claim 15 (depends on 1, 11)

A method of treating a patient comprising administering a compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, or a composition as claimed in claim 11.

### Claim 16 (depends on 1)

A process for the preparation of a compound of formula (I) as claimed in claim 1 comprising:
a. reductively aminating a compound of formula (II):
65
with an aldehyde R3CHO; or
b. where R1 is optionally substituted alkyl, reacting a compound of formula (III):
66
with an alkyl halide, in the presence of a base.
